Development and characterization of Adeno-associated virus-loaded coaxial electrospun scaffolds for potential viral vector delivery

分享:

简介:

  • 作者: Haiguang Zhang, Wei Dong, Qingxi Hu, Guanglang Zhu, and Jiaxuan Feng
  • 杂志: Authorea
  • 出版日期: 2025 Jan 10

论文中使用的产品/服务

询价

摘要

Gene therapy, which treats genetic diseases by fixing defective genes, has gained significant attention. Viral vectors show great potential for gene delivery but face limitations like low transduction efficiency and poor targeting. Loading viral vectors onto tissue engineered scaffolds presents a promising strategy to address these challenges, but their widespread application remains limited by challenges like vector stability, biomaterial selection, and high manufacturing costs. Adeno-associated virus (AAV), recognized for its safety, high efficiency, and low immunogenicity, was employed as a model virus. In this study, AAV was encapsulated within electrospun fibers (AAV/PCL-PEO@Co-ES) composed of polycaprolactone (PCL) and polyethylene oxide (PEO) via coaxial electrospinning, ensuring effective AAV protection and controlled release. The physicochemical characterization results indicated that the scaffold exhibited excellent mechanical properties (tensile strength: 3.22 ± 0.48 MPa) and wettability (WCA: 67.90 ± 8.45°). In vitro release and cell transduction assays demonstrated that the AAV-loaded scaffold effectively control viral vector release and transduction. Furthermore, the in vitro cell and in vivo animal experiments suggested that the AAV-loaded scaffolds exhibit excellent biocompatibility and efficient viral vector delivery capability. Hence, our research not only enhances the storage and delivery of viral vectors but also provides innovative solutions for viral vector delivery strategies.

关于派真

作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IITINDBLA的各个阶段。

 

凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。

下载